Blood
Articles in this Issue
A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study
Abstract Platzbecker U, Lane S and Adès L contributed equally. A study by the European Myelodysplastic Neoplasms Coopera...
LV20.19 CAR T cells for methotrexate relapsed/refractory primary or secondary CNS lymphoma with parenchymal involvement
Abstract Introduction: Relapsed, refractory (R/R) primary (PCSNL) and secondary central nervous system lymphoma (SCNSL) are difficult to tre...
Aberrant circulating CD4+ CD26- T-cells in T-cell rich B-cell lymphomas: Diagnostic pitfall or biomarker?
Abstract Background: Morphologically atypical, non-clonal T-cell infiltrates have been demonstrated in a subset of Nodul...
Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study
Abstract CD5-positive diffuse large B-cell lymphomas (DLBCL) represent 5-10% of all DLBCLs. This rare entity exhibits distinct clinical and...
The anti-MPL antibody AMM2 prevents cardiovascular dysfunction in a mouse model of myeloproliferative neoplasms
Abstract Introduction Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders marked by expansion of hematopoietic stem/progenito...
Disaggregating aggressive ATLL: A retrospective Study focused on the lymphomatous variant in Latin America
Abstract Background: The different subtypes of ATLL, as per the Shimoyama classification, are consistently described as distinct diseases in...
On the cellular origins of multiple myeloma
Abstract Introduction A long-standing question in multiple myeloma (MM) is the nature of its stem cell origin and whether transformation inv...
Socioeconomic disparities in the receipt of allogeneic stem cell transplantation among patients with relapsed Acute Myeloid Leukemia: A national inpatient sample analysis, 2016–2020
Abstract Introduction: Allogeneic stem cell transplantation (alloSCT) remains a cornerstone of curative-intent therapy for patients with rel...
Shear wave elastography as a screening modality for hepatic fibrosis in a comprehensive sickle cell disease clinic
Abstract Background: Sickle cell disease (SCD) is associated with a spectrum of liver complications, including sickle cell hepatopathy, driv...
RPS6 acts as a translational checkpoint to limit effector skewing and sustain CD8 T cell memory
Abstract Background: Durable CD8 T cell memory underpins protective immunity and effective immunotherapies. The mammalian target of rapamyci...
Single–cell analysis of BCR and transcriptome uncovers plasma cell clonal dynamics and immune exhaustion linked to daratumumab response in primary light–chain amyloidosis
Abstract Primary light–chain amyloidosis (pAL) is a systemic disorder driven by slowly proliferative clonal plasma cells that secrete misfol...
Cardiovascular disease in myelodysplastic syndromes and related disorders: Frequency, risk factors, and outcomes
Abstract Background Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations, which are also commonly observed in Myelodys...
Phase 2 trial of polatuzumab vedotin, rituximab and dose attenuated CHP in patients 75 years and older with large B-cell lymphoma
Abstract Introduction Older patients (pts) with large B-cell lymphoma (LBCL) are underrepresented on prospective clinical trials. Dose atten...
Daratumumab and venetoclax-based combined regimen for relapsed/refractory T-lymphoblastic leukemia/lymphoma
Abstract Objective: To investigate the efficacy and safety of a treatment regimen combining Daratumumab (Dara) with Venetoclax (Ven) in pati...
SOX11 skews T-cell development and synergizes with LMO2 and MYCN to form T-cell acute lymphoblastic leukemia in mouse models
Abstract Objective: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy accounting for 10%–15% of pediatric...
Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias
Abstract Background: T-cell Acute Lymphoblastic Leukemia (T-ALL) is characterized by the aggressive proliferation of imm...
Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study
Abstract Background: Mosunetuzumab is the first FDA- and EMA-approved CD20xCD3 T-cell engaging bispecific antibody for the treatment of R/R...
Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis
Abstract Purpose: Limited data exist detailing the outcomes with second-line (2L) systemic treatment of relapsed or refractory (R/R) periphe...
Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis
Abstract Background FMS-like tyrosine kinase 3(FLT3) mutations confer a high relapse risk in acute myeloid leukemia (AML) after allogeneic h...
Exploration of the role of macrophage mitochondrial damage-mediated excessive pyroptosis in ITP
Abstract Introduction Targeting macrophages is expected to become an important entry point for the study of the pathogenesis of ITP and the...
Pure IgA-mediated hemolytic anemia. a rare and challenging diagnosis of “Coombs Negative” hemolytic anemia, with successful management
Abstract Background: The diagnostic approach for patients with hemolytic anemia, typically involves assessment of an immune versus non-immun...
Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma
Abstract Introduction: Current chimeric antigen receptor (CAR) T cell therapies offer a valuable treatment option for patients with relapsed...
Predictive model based on post CAR-T cell therapy cytokine signature can help predict cytopenia
Abstract Introduction: Chimeric antigen receptor T-cells (CAR-T) are increasingly being utilized for the treatment of lymphomas....
Beyond age: Genomic features and treatment outcomes in older versus younger adults with Acute Myeloid Leukemia
Abstract Background: Median overall survival (mOS) in patients ≥60 years with newly diagnosed acute myeloid leukemia (AML) remains <10...
Single-cell profiling reveals MDSC-driven immunosuppressive remodeling of the tumor microenvironment mediates ruxolitinib resistance in myelofibrosis
Abstract Introduction Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal hematopoietic stem cell proliferation, bon...